Market News How it works Learn FAQ
| RCT 0.0923 21.29% | NU 12.5021 -17.53% | EWZ 34.02 -20.12% | BBD 2.877 -29.31% | TGL 0.2429 9.66% | AZTR 2.05 186.71% | ITUB 7.68 -20.58% | SRTM 0.2775 -35.51% | NVD 3.995 -4.65% | XP 15.4801 -49.10% | WFF 0.089 11.25% | SHFS 0.091 -31.27% | SPCX 149.37 1.27% | SOXL 92.37 10.54% | PBR 22.715 -13.17% | VALE 11.99 -3.31% | CLRO 4.84 48.92% | INTC 91.75 5.51% | GCDT 0.1443 -18.06% | TSLL 10.885 11.53% | NWGL 0.0872 6.34% | NOK 8.715 7.06% | NVDA 216.1126 2.44% | SOXS 46.95 -10.50% | CRWV 56.22 3.66% | BITO 10.695 -1.25% | RWM 14.475 -0.52% | GPUS 0.1858 10.01% | SGRY 23.185 47.21% | TSLG 5.445 11.81% | ABEV 2.805 -15.00% | JBLU 2.285 -12.95% | IREN 26.025 4.50% | INTR 4.595 -36.09% | RBNE 0.1682 -11.47% | QID 14.1701 -2.61% | AAL 12.1792 0.57% | TQQQ 68.8286 3.83% | SBS 4.6303 -27.65% | SPDN 8.485 -0.64% | TSLA 393.84 5.81% | T 20.6998 -1.10% | LUCD 0.538 30.90% | SID 0.9075 -23.09% | WULF 12.3201 8.83% | XTND 2.2899 29.37% | NFLX 63.005 -4.32% | CIFR 7.885 -0.69% | SQQQ 38.17 -3.81% | RIG 6.555 2.26%
RXRecursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ Global Select · Currency in USD
$3.80 ▲ +0.10 (+2.70%)
As of Oct 26, 3:14 PM ET. Market open.

Summary

Previous Close
$3.70
Open
$3.72
Day's Range
$3.64 – $3.86
52 Week Range
$2.77 – $6.50
Volume
12,637,434
Avg. Volume
22,289,911
Market Cap
$2.03B
Beta (5Y Monthly)
1.03
PE Ratio (TTM)
--
EPS (TTM)
-$0.97
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$5.90

Profile: Recursion Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
600
CEO
Najat Khan

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.22 · Revenue est. $14.81M
DateEst.Actual
Aug 5, 2026-$0.24-$0.25Miss
May 6, 2026-$0.30-$0.22Beat
Feb 25, 2026-$0.28-$0.21Beat
Nov 5, 2025-$0.38-$0.36Beat
Aug 5, 2025-$0.35-$0.41Miss
May 5, 2025-$0.44-$0.50Miss

Analyst view

Consensus price target
$5.90 ▲ +55.3%
Range $5.90 – $5.90
Rating: Hold
Buy 40% · Hold 60% · Sell 0%

Similar stocks

Get free alerts on RXRX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.